Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502) - simplywall.st

Earnings Tell The Story For Takeda Pharmaceutical Company Limited (TSE:4502)  simplywall.st

ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

ASCO 2025: Protagonist-Takeda, Novartis post phase III wins  BioWorld MedTech

Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle - korea...

Takeda’s market exit and return of vonoprazan raise stakes in Korea’s drug pricing battle  koreabiomed.com

Takeda PH promotes equitable access to medicines at SEA Summit - Philippine News Agency

Takeda PH promotes equitable access to medicines at SEA Summit  Philippine News Agency

Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti - koreabi...

Korean pharmas race for generic P-CAB market amid Takeda's uncertain future for Vocinti  koreabiomed.com

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? - Yahoo Finance

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?  Yahoo Finance

Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing - Fierc...

Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing  Fierce Biotech

Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures - BioSpace

Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures  BioSpace

Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal - Substack

Scoop: San Diego Biotech Partners with Takeda, Lands $1.2B Milestone Deal  Substack

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide ...

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera  Business Wire

How This Takeda Technology Exec Is Embracing The Possibilities 04/24/2025 - MediaPost

How This Takeda Technology Exec Is Embracing The Possibilities 04/24/2025  MediaPost

Takeda's Strategic Positioning in a Turbulent Biopharma Landscape: A Blueprint for Long-Term Outp...

Takeda's Strategic Positioning in a Turbulent Biopharma Landscape: A Blueprint for Long-Term Outperformance  AInvest

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris - The Motley Fool

Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris  The Motley Fool

YOASOBI and Ayano Takeda Discuss Pokémon Collaboration ‘Biri-Biri’ - Billboard

YOASOBI and Ayano Takeda Discuss Pokémon Collaboration ‘Biri-Biri’  Billboard

Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data d...

Neurocrine-Takeda med reduces depression severity in phase 2, though analysts ask for more data detail  Fierce Biotech

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? - Yahoo Finance

Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?  Yahoo Finance

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndro...

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome  Business Wire

Takeda's Poseida partnership starts to pay off with promising hemophilia A gene therapy data - Fi...

Takeda's Poseida partnership starts to pay off with promising hemophilia A gene therapy data  Fierce Biotech

Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company - koreabiome...

Takeda taps Julie Kim as next CEO, 1st Korean American to lead global pharma company  koreabiomed.com

Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on t...

Takeda-backed Poseida puts off-the-shelf CAR-T in its basket, places autologous therapy back on the shelf  Fierce Biotech

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India - Indian Pharma Post

Mankind Pharma signs agreement with Takeda to commercialize Vonoprazan in India  Indian Pharma Post

Torrent Pharma in pact with Takeda to commercialize acid reflux drug - Mint

Torrent Pharma in pact with Takeda to commercialize acid reflux drug  Mint

Torrent Pharma, Takeda to commercialise GI drug in India - Times of India

Torrent Pharma, Takeda to commercialise GI drug in India  Times of India

Zydus Licenses Takeda's GERD Drug Vonoprazan for India - Rediff MoneyWiz

Zydus Licenses Takeda's GERD Drug Vonoprazan for India  Rediff MoneyWiz

Torrent Pharma Licenses Vonoprazan GERD Drug from Takeda - Rediff MoneyWiz

Torrent Pharma Licenses Vonoprazan GERD Drug from Takeda  Rediff MoneyWiz

Lupin Joins Hands With Japans Takeda To Sell Vonoprazan In India - NDTV Profit

Lupin Joins Hands With Japans Takeda To Sell Vonoprazan In India  NDTV Profit

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologi...

Pioneering Drug Discovery Company Bridge Medicines Launched to Advance Promising Early Technologies in Major Academic Institutions through Human Proof of Concept  WCM Newsroom

Takeda signs patent license agreement with Cipla, Sun Pharma to commercialise GERD drug in India ...

Takeda signs patent license agreement with Cipla, Sun Pharma to commercialise GERD drug in India  BioSpectrum India

Zydus ties with Takeda to sell GERD drug - Mint

Zydus ties with Takeda to sell GERD drug  Mint

Takeda Pharmaceutical names Serina Fischer as head of India operations - ETHRWorld.com

Takeda Pharmaceutical names Serina Fischer as head of India operations  ETHRWorld.com

Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault’ (Vonoprazan) in ...

Zydus announces non-exclusive patent licensing agreement with Takeda for ‘Vault’ (Vonoprazan) in India  Express Pharma

Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in ...

Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in India  The Economic Times

Mankind Pharma inks pact with Takeda to commercialise acidity drug in India - Business Standard

Mankind Pharma inks pact with Takeda to commercialise acidity drug in India  Business Standard

Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India - Business Standard

Lupin joins hand with Takeda to Launch Vonoprazan Tablets in India  Business Standard

Cipla signs agreement with Takeda to commercialise Vonoprazan - Express Pharma

Cipla signs agreement with Takeda to commercialise Vonoprazan  Express Pharma

Takeda, Frazier Healthcare Partners to launch Phathom Pharma - BioSpectrum Asia

Takeda, Frazier Healthcare Partners to launch Phathom Pharma  BioSpectrum Asia

Torrent pharma inks licensing pact with Takeda to commercialise GERD drug - Zee Business

Torrent pharma inks licensing pact with Takeda to commercialise GERD drug  Zee Business

Mankind Pharma signs agreement with Takeda to commercialise novel drug for GERD treatment in Indi...

Mankind Pharma signs agreement with Takeda to commercialise novel drug for GERD treatment in India  financialexpress.com